👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Biogen Rises On Upgrades, Findings Of Trial In Spinal Muscular Atrophy

Published 06/11/2021, 02:03 AM
© Reuters.
BIIB
-
UBS
-
IONS
-
MNDY
-

By Dhirendra Tripathi

Investing.com – Biogen (NASDAQ:BIIB) shares rose 4% Thursday following two upgrades as well as new findings showing benefits from a higher dose of a medicine it makes to treat patients suffering from spinal muscular atrophy.

Biogen licensed the global rights to develop, manufacture and commercialize the medicine, Spinraza, from Ionis Pharmaceuticals (NASDAQ:IONS). Ionis shares gained by more than 3%.

The data showed benefits to patients over the long term.

Two brokerages, SVB Leerink and UBS (NYSE:UBS), upgraded the stock to a ‘buy’ on the same day.

SVB Leerink has kept its target for the stock at $475, 12.5% from the stock’s current level of $422. UBS’s $463 target is 9.7% more from the prevailing price.

Biogen made headlines Monday (NASDAQ:MNDY) when its aducanumab became the first medicine in 18 years to secure U.S. Food and Drug Administration’s authorization to treat Alzheimer’s.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.